Carmen Doris Garzón-Olivares, Carlos Fernando Grillo-Ardila, Jairo Amaya-Guio, Maria Teresa Vallejo-Ortega, Luz Amparo Diaz-Cruz, Carolina Fernández-Motta, Alejandra Del Pilar Gomez-Motta, Alina Tatiana Barrera, Lina María Trujillo-Sánchez, Carlos Humberto Pérez-Moreno, Luis Jairo Bonilla-Osma, Robinson Fernández-Mercado, Néstor Augusto Giraldo-Méndez, Jorge Eduardo Caro-Caro, Amparo Leonor Ramírez-Corredor, Dayanne Milecsy Rodríguez-Hernádez
Background: Primary screening with Human Papilloma Virus (HPV) testing was introduced in Colombia in 2014 for individuals between 30 and 65 years of age. When the result is positive, cytology triage is performed for colposcopy referral. The convenience of initiating HPV-DNA testing for screening at 25 years of age is currently a subject of discussion. Therefore, the objective of this health technology assessment (HTA) is to analyze the available evidence regarding safety, efficacy, cost-effectiveness, values and preferences, ethical dilemmas and considerations pertaining to the implementation of the HPV-DNA test as a cervical screening strategy in women under 30 years of age in the Colombian context...
June 30, 2022: Revista Colombiana de Obstetricia y Ginecología